Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection

por Lederman, Michael M, Jump, Robin, Pilch-Cooper, Heather A, Root, Michael, Sieg, Scott F
Publicado 2008

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine

por Funderburg, Nicholas T., Andrade, Adriana, Chan, Ellen S., Rosenkranz, Susan L., Lu, Darlene, Clagett, Brian, Pilch-Cooper, Heather A., Rodriguez, Benigno, Feinberg, Judith, Daar, Eric, Mellors, John, Kuritzkes, Daniel, Jacobson, Jeffrey M., Lederman, Michael M.
Publicado 2013

Prevention of SHIV transmission by topical IFN-β treatment

por Veazey, Ronald S., Pilch Cooper, Heather A., Hope, Thomas J., Alter, Galit, Carias, Ann M., Sips, Magdalena, Wang, Xiaolei, Rodriguez, Benigno, Sieg, Scott F., Reich, Adrian, Wilkinson, Peter, Cameron, Mark J., Lederman, Michael M.
Publicado 2016

Interferon-α Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers

por Hardy, Gareth A. D., Sieg, Scott, Rodriguez, Benigno, Anthony, Donald, Asaad, Robert, Jiang, Wei, Mudd, Joseph, Schacker, Timothy, Funderburg, Nicholas T., Pilch-Cooper, Heather A., Debernardo, Robert, Rabin, Ronald L., Lederman, Michael M., Harding, Clifford V.
Publicado 2013